PDF Download
PubReader
Export Citation
Email the Author
Share Facebook
Share Twitter
Cited by 0 Article
Metrics (View:956)- Legal and Ethical Issues concerning the Fair Competition Code on Pharmaceutical Trade
QR Code of this Article:
Related Articles
Reinforcing Professionalism through Medical Ethics Education Based on Arete
Korean J Med Ethics 2021;24(4):409-422.
Using Delphi surveys to identify the core competencies of medical ethics for inclusion in the Korean Medical Licensing Examination
Korean J Med Ethics 2020;23(2):81-97.
The Future of Medical Ethics from an Engineering Perspective: Treatment or Repair?*
Korean J Med Ethics 2019;22(3):274-286.
A Three-fold Approach to Medical Ethics Education That Combines Quantitative and Qualitative Reasoning
Korean J Med Ethics 2018;21(3):241-261.
Exploration of the Biomedical Ethics Education Module Used in the UNESCO Bioethics Core Curriculum
Korean J Med Ethics 2016;19(3):282-296.
의약품 거래에 관한 세 가지 규약의 법적 관계 및 쟁점별 비교·고찰*
Received: Apr 20, 2010; Accepted: Jun 01, 2010
Published Online: Jun 30, 2010
ABSTRACT
In 2007 the Korean Research-based Pharmaceutical Industry Association (KRPIA) developed a Fair Competition Code on Pharmaceutical Trade, and in 2010 the Korean Pharmaceutical Manufacturers Association (KPMA) revised its Code of Fair Competition. Prior to 2007, the KRPIA and KPMA made voluntary agreements on pharmaceutical trade. This article examines the three codes in terms of the limits they set on various forms of gift-giving, donations, the funding of academic conferences inside and outside of Korea, the provision of drugs for clinical studies, market surveys, and post-market surveillance studies. The results of this examination show that the KPMA 2010 Code reflects a moral bias against donations to healthcare organizations and grants an exclusive power to the KPMA regarding sponsorships to participate in academic conferences.